<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-8 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-8</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-8</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>primary_immunotherapy</strong></td>
                        <td>str</td>
                        <td>The name of the primary immunotherapy that patients developed resistance to (e.g., 'pembrolizumab', 'nivolumab', 'ipilimumab', 'anti-PD-1', 'anti-CTLA-4', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>immunotherapy_class</strong></td>
                        <td>str</td>
                        <td>The class/type of the primary immunotherapy (e.g., 'checkpoint inhibitor', 'anti-PD-1', 'anti-PD-L1', 'anti-CTLA-4', 'adoptive cell therapy', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>resistance_type</strong></td>
                        <td>str</td>
                        <td>Is this primary/intrinsic resistance or acquired/late resistance? Be explicit. (e.g., 'acquired resistance', 'late resistance', 'primary resistance', 'intrinsic resistance')</td>
                    </tr>
                    <tr>
                        <td><strong>resistance_mechanism</strong></td>
                        <td>str</td>
                        <td>What is the biological mechanism of resistance described? Be specific about pathways, mutations, or immunological changes (e.g., 'loss of PTEN', 'upregulation of alternative immune checkpoints', 'T cell exhaustion', 'loss of antigen presentation', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>combination_strategy_name</strong></td>
                        <td>str</td>
                        <td>The name or brief label for the combination therapy strategy being tested (e.g., 'anti-PD-1 + MEK inhibitor', 'dual checkpoint blockade', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>combination_agents</strong></td>
                        <td>str</td>
                        <td>List all therapeutic agents used in the combination strategy, with specific drug names when available (e.g., 'nivolumab + trametinib', 'pembrolizumab + ipilimumab + targeted therapy')</td>
                    </tr>
                    <tr>
                        <td><strong>combination_rationale</strong></td>
                        <td>str</td>
                        <td>What is the scientific/mechanistic rationale for this specific combination? Why were these agents combined?</td>
                    </tr>
                    <tr>
                        <td><strong>study_type</strong></td>
                        <td>str</td>
                        <td>Is this preclinical (cell lines, animal models) or clinical evidence? Be specific (e.g., 'phase I clinical trial', 'phase II clinical trial', 'mouse model', 'patient-derived xenograft', 'retrospective clinical analysis', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>patient_population</strong></td>
                        <td>str</td>
                        <td>Description of the patient population or model system (e.g., 'melanoma patients who progressed on prior anti-PD-1 therapy', 'BRAF-mutant melanoma', 'treatment-naive', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>clinical_outcomes</strong></td>
                        <td>str</td>
                        <td>What were the clinical or therapeutic outcomes? Include specific metrics like response rate, progression-free survival, overall survival, etc. with numerical values and units (e.g., 'ORR 45%, median PFS 8.2 months', null if no information)</td>
                    </tr>
                    <tr>
                        <td><strong>biomarkers_predictive</strong></td>
                        <td>str</td>
                        <td>Were any biomarkers identified that predict response to the combination therapy or resistance? (e.g., 'high PD-L1 expression', 'tumor mutational burden', 'IFN-gamma signature', null if none mentioned)</td>
                    </tr>
                    <tr>
                        <td><strong>timing_sequence</strong></td>
                        <td>str</td>
                        <td>Is there information about the timing or sequencing of the combination? (e.g., 'simultaneous', 'sequential', 'immunotherapy first then targeted therapy', null if not specified)</td>
                    </tr>
                    <tr>
                        <td><strong>toxicity_safety</strong></td>
                        <td>str</td>
                        <td>Were there any toxicity or safety concerns mentioned with the combination? (e.g., 'grade 3-4 adverse events in 30%', 'well-tolerated', null if not mentioned)</td>
                    </tr>
                    <tr>
                        <td><strong>comparison_to_monotherapy</strong></td>
                        <td>bool</td>
                        <td>Does the paper provide a direct comparison between the combination therapy and monotherapy in the resistance setting? (true, false, or null for no information)</td>
                    </tr>
                    <tr>
                        <td><strong>overcomes_resistance</strong></td>
                        <td>bool</td>
                        <td>Does the evidence suggest this combination successfully overcomes acquired immunotherapy resistance? (true, false, or null for no information)</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>